Tanabe Pharma Europe Ltd was originally established in 2001 as Mitsubishi Pharma Europe Ltd, with its headquarters in London. On 1st June 2014, the company was renamed Mitsubishi Tanabe Pharma Europe Ltd (MTPE) to align with its parent company, Mitsubishi Tanabe Pharma Corporation (MTPC). In 2020, MTPC became a wholly owned subsidiary of Mitsubishi Chemical Group Corporation.
Following the acquisition of MTPC by Bain Capital in 2025, the Company has since been rebranded as Tanabe Pharma Europe Ltd.
Tanabe Pharma Europe Ltd oversees the management of clinical research activities on behalf of Tanabe Pharma Corporation across the European Union (EU) and other associated European territories.
Our German subsidiary, Tanabe Pharma GmbH, is responsible for Business operations throughout the region.
Clinical Research and Development Operations
- Development of clinical study programmes
- Management of clinical studies
- Data handling & reporting
- Importation and preparation of clinical study supplies
- Management of European safety reporting during clinical studies
- Submission of marketing applications
Commercial Operations
- Sale/supply of medicinal products in Europe and related territories.
- Marketing and distribution of Tanabe Pharma Corp’s medicinal products by TPE, affiliates or licensees.
- Supply of products, drug substances and raw materials to affiliates and licensees.
Our clinical research operations have been established in Europe since 2001 and we are currently supporting the development of compounds in a number of disease areas.
During the summer of 2005, we commenced commercial operations when we launched our first European product in Germany then followed by in other countries.
Terms and Privacy
Contact Us
TANABE Pharma Europe Ltd
Dashwood House
69 Old Broad Street
London
EC2M 1QS
United Kingdom